Abstract
Genistein, one of the most active natural flavonoids, exerts various biological effects including chemoprevention, antioxidation, antiproliferation and anticancer. More than 30 clinical trials of genistein with various disease indications have been conducted to evaluate its clinical efficacy. Based on many animals and human pharmacokinetic studies, it is well known that the most challenge issue for developing genistein as a chemoprevention agent is the low oral bioavailability, which may be the major reason relating to its ambiguous therapeutic effects and large interindividual variations in clinical trials. In order to better correlate pharmacokinetic to pharmacodynamics results in animals and clinical studies, an in-depth understanding of pharmacokinetic behavior of genistein and its ADME properties are needed. Numerous in vitro/in vivo ADME studies had been conducted to reveal the main factors contributing to the low oral bioavailability of genistein. Therefore, this review focuses on summarizing the most recent progress on mechanistic studies of genistein ADME and provides a systemic view of these processes to explain genistein pharmacokinetic behaviors in vivo. The better understanding of genistein ADME property may lead to development of proper strategy to improve genistein oral bioavailability via mechanism-based approaches.
Keywords: Genistein, Flavonoids, Isoflavone, Bioavailability, Pharmacokinetics, ADME, Metabolism, Transporter, BCRP, estrogen-dependent breast, preneoplastic cells
Anti-Cancer Agents in Medicinal Chemistry
Title:Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Volume: 12 Issue: 10
Author(s): Zhen Yang, Kaustubh Kulkarni, Wei Zhu and Ming Hu
Affiliation:
Keywords: Genistein, Flavonoids, Isoflavone, Bioavailability, Pharmacokinetics, ADME, Metabolism, Transporter, BCRP, estrogen-dependent breast, preneoplastic cells
Abstract: Genistein, one of the most active natural flavonoids, exerts various biological effects including chemoprevention, antioxidation, antiproliferation and anticancer. More than 30 clinical trials of genistein with various disease indications have been conducted to evaluate its clinical efficacy. Based on many animals and human pharmacokinetic studies, it is well known that the most challenge issue for developing genistein as a chemoprevention agent is the low oral bioavailability, which may be the major reason relating to its ambiguous therapeutic effects and large interindividual variations in clinical trials. In order to better correlate pharmacokinetic to pharmacodynamics results in animals and clinical studies, an in-depth understanding of pharmacokinetic behavior of genistein and its ADME properties are needed. Numerous in vitro/in vivo ADME studies had been conducted to reveal the main factors contributing to the low oral bioavailability of genistein. Therefore, this review focuses on summarizing the most recent progress on mechanistic studies of genistein ADME and provides a systemic view of these processes to explain genistein pharmacokinetic behaviors in vivo. The better understanding of genistein ADME property may lead to development of proper strategy to improve genistein oral bioavailability via mechanism-based approaches.
Export Options
About this article
Cite this article as:
Yang Zhen, Kulkarni Kaustubh, Zhu Wei and Hu Ming, Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/187152012803833107
DOI https://dx.doi.org/10.2174/187152012803833107 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Designing Novel Molecules for Anti-Cancer Enzyme Modulation: A Mechanistic and Therapeutic Perspective
The deficiencies or hyper functions of enzymes cause a number of diseases. Enzyme inhibition is an important area of pharmaceutical research since studies in this field have already led to the discovery of wide variety of drugs useful in a number of diseases. Specific inhibitors interact with enzymes and block ...read more
Discovery Of Lead Compounds Targeting Transcriptional Regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy
The thematic issue, "Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy," explores the critical role of heterocyclic compounds in advancing the frontiers of cancer treatment. Heterocycles serve as fundamental building blocks in medicinal chemistry due to their structural diversity and ability to interact with biological targets. This issue aims ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CD93: Recent Advances and Implications in Disease
Current Drug Targets Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Editorial (Thematic Issue: Polymeric Nanomedicines for Malignancy Therapy)
Current Pharmaceutical Biotechnology Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release
Current Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Current Status and Perspectives Regarding the Treatment of Osteosarcoma: Chemotherapy
Reviews on Recent Clinical Trials Anti-tumor Activity of Propofol: A Focus on MicroRNAs
Current Cancer Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Current Genome Editing Tools in Gene Therapy: New Approaches to Treat Cancer
Current Gene Therapy Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Recent Progress in the Hesperetin Delivery Regimes: Significance of Pleiotropic Actions and Synergistic Anticancer Efficacy
Current Pharmaceutical Design Up-regulation of Core 1 Beta 1, 3-Galactosyltransferase Suppresses Osteosarcoma Growth with Induction of IFN-γ Secretion and Proliferation of CD8<sup>+</sup> T Cells
Current Cancer Drug Targets Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry